Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-09-30

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality.

One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT02282436

Chronic Obstructive Pulmonary Disease

UNKNOWN

Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of COPD

NCT03153826

Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Copd Muscle Atrophy

TERMINATED NA

Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD

NCT01909544

Pulmonary Disease, Chronic Obstructive

UNKNOWN NA

Resistance Training to Prehabilitate Patients With Chronic Obstructive Pulmonary Disease

NCT02860728

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy

NCT01344135

Pulmonary Disease, Chronic Obstructive Muscular Atrophy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD patients

Group : COPD patients No specific intervention for this study

No specific intervention for this study

Intervention Type OTHER

No specific intervention for this study

Healthy controls

Group : healthy volunteers No specific intervention for this study

No specific intervention for this study

Intervention Type OTHER

No specific intervention for this study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No specific intervention for this study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male
* COPD with an FEV1 of under 60% of predicted
* non-smoker
* between 55 and 75 years old

Exclusion Criteria

* all inflammatory disease (HIV, cancer, renal and cardiac deficiency)
* hormonal dysregulation
* inferior limb pathology
* neuromuscular pathology
* history of tobacco or alcool abuse
* oxygen dependent
* recent exacerbation (2 months) of the symptoms of COPD

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes